Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

Affiliations

• ¹ Istituto Europeo di Oncologia, IRCCS, Milano, Italy. [email protected].
• ² University of Milan, Milano, Italy. [email protected].
• ³ Dana-Farber Cancer Institute, Boston, MA, USA.
• ⁴ University College London, Cancer Institute, London, UK.
• ⁵ Phase 1 Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.
• ⁶ University of Colorado Cancer Center, Aurora, CO, USA.
• ⁷ Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
• ⁸ Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
• ⁹ BC Cancer, Vancouver, BC, Canada.
• ¹⁰ University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL, USA.
• ¹¹ University of Michigan/Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
• ¹² University of Oxford, Oxford, UK.
• ¹³ Fox Chase Cancer Center, Philadelphia, PA, USA.
• ¹⁴ University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
• ¹⁵ Pfizer, San Diego, CA, USA.
• ¹⁶ Pfizer, Groton, CT, USA.
• ¹⁷ Celcuity, Minneapolis, MD, USA.
• ¹⁸ David Geffen School of Medicine at University of California, Los Angeles, CA, USA.